Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Camoteskimab in Subjects With Adult Onset Still's Disease

NCT04752371 is registered in ClinicalTrials.gov with Apollo Therapeutics Ltd as lead sponsor.

NCT NCT04752371
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04752371 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Camoteskimab in Subjects With Adult Onset Still's Disease
Lead sponsor
Apollo Therapeutics Ltd
Phase
Phase 1
Overall status
Terminated
Start date
March 25, 2021
Completion date
May 24, 2022
Enrollment
5 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

adult onset still's disease